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Objective  To evaluate the spasticity and electrophysiologic eff  ects of applying extracorporeal shock wave therapy 
(ESWT) to the gastrocnemius by studying F wave and H-refl  ex.
Method  Ten healthy adults and 10 hemiplegic stroke patients with ankle plantarflexor spasticity received one 
session of ESWT on the medial head of the gastrocnemius. The modified Ashworth scale (MAS), tibial nerve 
conduction, F wave, and H-refl  ex results were measured before and immediately after the treatment. Th  e  Visual 
Analogue Scale (VAS) was used during ESWT to measure the side eff  ects, such as pain.
Results  There were no significant effects of ESWT on the conduction velocity, distal latency and amplitude of 
tibial nerve conduction, minimal latency of tibial nerve F wave, latency, or H-M ratio of H-reflex in either the 
healthy or stroke group. However, the MAS of plantarfl  exor was signifi  cantly reduced from 2.67±1.15 to 1.22±1.03 
(p<0.05) after applying ESWT in the stroke group.
Conclusion  After applying ESWT on the gastrocnemius in stroke patients, the spasticity of the ankle plantarfl  exor 
was significantly improved, with no changes of F wave or H-reflex parameters. Further studies are needed to 
evaluate the mechanisms of the antispastic eff  ect of ESWT.
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INTRODUCTION
  Spasticity is one of the most important causes of 
disability in stroke patients; it interferes with the patients’ 
rehabilitation, especially regarding functional recovery.
1 
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Because the primary lesion causing spasticity is located 
in the central nervous system, most studies have focused 
on the neural mechanisms such as excessively increased 
spinal excitability as the primary cause of spasticity.
2,3 
In recent years, there have been several reports that 
chronic spasticity itself plays a role in the increase of 
joint resistance by structural and mechanical changes in 
skeletal muscles through fi  brosis of connective tissue.
4
  Recent studies have reported that intramuscular 
injections of botulinum toxin type A reduces spasticity 
in hypertonic muscles of the upper limb or equinovarus 
deformity by lower limb spasticity, and improves 
functional abilities.
5-7 However, the development of 
neutralizing antibodies can reduce the efficacy of Min Kyun Sohn, et al.
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MATERIALS AND METHODS
Subjects
  Ten healthy adults (4 males and 6 females, mean age of 
25.8±3.1 years) and 10 hemiplegic stroke patients with 
ankle plantarflexor spasticity (6 males and 4 females, 
mean age of 44.9±11.3 years) were enrolled for this study. 
Two patients had ischemic stroke, and 8 patients had 
hemorrhagic stroke. Two patients had cortical lesions, 3 
patients had thalamic lesions, and 5 patients had basal 
ganglia lesions. All patients had a spasticity greater than 
grade I, by modifi  ed Ashworth scale (MAS) and were in a 
chronic stage for over 15 months. Patients with previous 
or planned treatment of the limb with botulinum toxin, 
phenol, or intrathecal baclofen pump were excluded. 
All patients were receiving antispastic pharmacological 
therapy and did not change the dose of antispastic 
medication during the study (Table 1).
Extracorporeal shock wave therapy
  Evotron
® (SwiTech, Kreuzlingen, Switzerland) was used 
for ESWT. Th   e pressure pulses were focused at the medial 
head of the gastrocnemius of the spastic side. Shots 
(1,500) were given in the middle of the belly and the 
intensity was 0.1 mJ/mm
2. In the healthy control group, 
the same methods of ESWT were applied at the right side 
medial head of the gastrocnemius. R20 with the focusing 
treatment for some patients. In addition, the dosage of 
botulinum toxin is not always suffi   cient to treat extensive 
and severe hypertonia in the upper and lower limbs. 
Chronic hypertonic muscles can lead to the fibrosis 
of connective tissue, and should be considered in the 
rehabilitation of stiff   joints.
8 
  Extracorporeal shock wave therapy (ESWT), defined 
as a sequence of single sonic pulses characterized by 
high peak pressure (100 MPa), fast pressure rise (<10 
ns), and short duration (10 μs), is conveyed by an 
appropriate generator to a specific target area with an 
energy density in the range of 0.003-0.890 mJ/mm
2. 
ESWT was first applied to patients in 1980 to break up 
kidney stones.
9 Recent studies have indicated that ESWT 
is effective for treatment of musculoskeletal diseases 
such as pseudoarthrosis, calcific tendinitis of shoulder, 
epicondylitis, plantar fasciitis, and several infl  ammatory 
tendon diseases.
10-13 Mariotto et al.
14 reported that ESWT 
induced nitric oxide (NO) synthesis, and NO plays a 
critical role in anti-infl  ammatory responses.
  The amplitude of the F wave and the F-M ratio reflect 
the excitability of motor neurons and are increased 
by spasticity.
15-17 Many studies have reported that the 
amplitude of the F wave and the F-M ratio can be used as 
tools for measuring the spasticity electrophysiologically. 
Latency of H-reflex and H-M ratio, which reflect the 
excitability of α motor neurons, can also be used as a tool 
for measuringspasticity.
18,19
  Manganotti and Amelio
20 reported that ESWT on 
the flexor hypertonic muscles of the forearm and the 
interosseus muscles of the hand was effective for the 
improvement of upper limb spasticity in stroke patients 
for >12 weeks; 1,500 shots were used to treat flexor 
muscles of the forearm and 800 shots for each interosseus 
muscle of the hand with 0.030 mJ/mm
2 intensity. Yoo 
et al.
21 reported significantly reduced spasticity on the 
elbow flexor and wrist pronator for 1 to 4 weeks after 
1,000 shots of ESWT with 0.069 mJ/mm
2 intensity; 
however, there was no report on ESWT’s therapeutic 
eff  ect on lower limb spasticity for stroke patients, and it’s 
mechanism is still unknown. The goal of this study was 
to evaluate the spasticity and electrophysiologic effects 
by studying F wave and H-reflex after applying ESWT 
on the gastrocnemius in stroke patients with lower limb 
spasticity.
Table 1. General Characteristics of Subjects
Characteristics
Healthy controls 
(n=10)
Stroke patients
(n=10)
Age (years) 25.8 ± 3.1 44.9 ± 11.3
Gender, male/female 4/6 6/4
Diagnosis
  Infarction 2
  Hemorrhage 8
Site of lesion
  Cortex 2
  Th  alamus 3
  Basal ganglia 5
Time since onset
 (months)
53.4±23.9
MAS 2.67±1.15
Values are means±standard deviation
MAS: Modifi  ed Ashworth scaleSpasticity and Electrophysiologic  Changes after ESWT
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depth of 20-30 mm was used for the head of ESWT to 
minimize or avoid stimulation of the soleus. 
Clinical and electrophysiologic evaluation
  F wave and H-refl  exes of the tibial nerve were recorded 
before and immediately after the treatment to assess the 
electrophysiologic eff  ects of ESWT on spasticity. Medelec 
Synergy
® (Viasys healthcare, San Diego, USA) was used 
for electrophysiologic assessment and all studies were 
performed by one rehabilitation physiatrist. In the F 
wave study, an active recording electrode was placed in 
the abductor hallucis muscle and the reference electrode 
was at the proximal interphalangeal joint of the great 
toe. Supramaximal stimulation of the tibial nerve was 
done 20 times on the posterior area of the ankle medial 
malleolus using antidromic conduction, and the F wave’s 
minimal latency was recorded. The sweep speed was 
5-10 ms/div, sensitivity was 200-500 μV/div, and the fi  lter 
range was 20-10,000 Hz. In the H-refl  ex study, the active 
recording electrode was placed in the soleus muscle 
and the reference electrode in the Achilles tendon. To 
evoke H-refl  ex, the posterior tibial nerve was stimulated 
in popliteal fossa with 0.2 Hz frequency and 0.5 ms 
duration. We gradually increased stimulation intensity 
and recorded H-reflex latency and H-M ratio using 
the maximal amplitude of H-reflex and M wave. Distal 
latency, amplitude of compound muscle action potential, 
and conduction velocity of the tibial nerve were recorded 
to assess the peripheral nerve injury by ESWT.
  Modifi  ed Ashworth Scale (MAS) was used to assess the 
spasticity of an ankle plantarflexor. MAS is a velocity-
independent method which manually assesses the 
joint range of motion. For convenience of statistical 
analysis, MAS grade 1+ was matched to  point 2; grades 
2, 3 and 4 were matched to 3, 4 and 5, respectively.
22 To 
avoid inter-rater bias, all studies were performed by one 
rehabilitation physiatrist.
  The Visual Analogue Scale (VAS) was used to estimate 
the severity of pain produced by ESWT. A vertical line 
with 10 cm length on paper was presented to the subjects 
and the subjects were told that  the lower end of the line 
indicated “pain-free state” and the upper end indicated 
“can not endure because of too severe pain.” After ESWT, 
all subjects were drawing the perpendicular line on the 
vertical line based on their pain experienced during 
treatment. Vertical lines were divided by 10 grades with 1 
cm intervals, and this  indicated the degree of pain.
23
Statistical analysis
  MAS, F-wave minimal latency, H-reflex latency, H-M 
ratio, and tibial nerve distal motor conduction study 
before and immediately after ESWT were analyzed by 
the Wilcoxon signed rank test using SPSS 17.0, Korean 
version. A p<0.05 was considered statistically signifi  cant.
RESULTS
Healthy controls
  No significant changes were found in the F wave 
minimal latency, H-reflex latency or H-M ratio after 
ESWT in healthy controls. Likewise, changes in the 
latency, amplitude of compound muscle action potential 
Table 2. Eff  ect of ESWT on Spasticity and Electrophysiologic Findings
Healthy controls Stroke patients
Before After Before After
CMAP latency (ms)     3.33±0.39   3.36±0.32   3.80±0.69   4.00±0.60
CMAP amplitude (mV) 15.83±3.4 15.91±3.18 13.02±3.09 13.09±3.30
Tibial nerve conduction velocity (m/s)   52.80±2.44 53.72±2.95 50.94±3.95 51.12±4.25
F wave min. latency (ms)   37.63±2.82 37.23±2.89 41.82±3.89 41.57±2.88
H-refl  ex latency (ms)   28.27±1.66 28.00±1.62 30.77±1.17 30.94±1.43
H-M ratio     3.74±1.64   3.62±1.89    5.63±2.98    5.76±3.12
MAS    2.67±1.15      1.22±1.03*
Values are means±standard deviation
ESWT: Extracorporeal shock wave therapy, CMAP: Compound muscle action potential of tibial nerve, F wave min. 
latency: F wave minimal latency of tibial nerve
*p<0.05 with Wilcoxon signed rank testMin Kyun Sohn, et al.
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and conduction velocity of the tibial nerve were not 
significant (Table 2). Mild pain was experienced during 
ESWT, VAS 2.87±1.49.
Change of ankle plantarﬂ  exor spasticity in stroke 
patients
  In stroke patients, MAS of ankle plantarflexor before 
treatment was 2.67±1.15, and was significantly reduced 
to 1.22±1.03 immediately after ESWT (p<0.05) (Table 2). 
Also, mild pain  (VAS 3.23±1.28) was produced by ESWT.
Electrophysiologic changes in stroke patients
  In stroke patients, F wave minimal latency, H-reflex 
latency, and H-M ratio before treatment were 41.82±3.89 
ms, 30.77±1.17 ms, and 5.63±2.98, respectively. 
Immediately after treatment, they were 41.57±2.88 ms, 
30.94±1.44 ms, and 5.76±3.12 ms, respectively. There 
were no signifi  cant changes after treatment (Table 2).
  In stroke patients, the latency and amplitude of tibial 
nerve compound muscle action potential before 
treatment were each 3.80±0.69 ms and 13.02±3.10 mA. 
Immediately after treatment, these values were 4.00±0.60 
ms and 13.09±3.30 mA, respectively, and no significant 
changes were noted after treatment (Table 2). Also, there 
was no significant change of tibial nerve conduction 
velocity from 50.94±3.95 m/s before treatment to 51.12± 
4.25 m/s after treatment (Table 2).
  
DISCUSSION
  ESWT is known to be effective in musculoskeletal 
diseases for treating pain, inflammation, or injury of a 
ligament. ESWT produces mechanical effects such as 
regeneration of degenerated tissue, neovascularization, 
and resorption of calcium deposit,
24,25 and also 
physiological responses such as changes of epithelial 
cell permeability, free radical formation, change of cell 
membrane permeability, NO formation, and variable 
growth factor formation.
14, 20, 26 
  The mechanisms of ESWT on spasticity due to central 
nervous system injury are still unknown. Mariotto et 
al.
14 stated that ESWT can induce NO synthesis and NO 
is involved in improvement of variable tendon disease. 
NO is involved in neuromuscular junction formation 
in the peripheral nervous system
27 and in physiological 
functions of the central nervous system, including 
neurotransmission, and synaptic plasticity.
28 
  Likewise, variable mechanisms have been proposed, 
including acting on fibrosis of chronic hypertonic 
muscles,
20 decreasing spinal excitability,
29 and 
mechanical vibratory stimulation.
29 Considering the 
therapeutic effects of ESWT on bones and tendons 
Manganotti and Amelio
20 proposed that reduction of 
spasticity could be caused by improving the stiffness of 
connective tissue by directly acting on fi  brosis of chronic 
hypertonic muscles.
  In this study, we attempted to evaluate the antispastic 
mechanism of ESWT by using F waves and H-reflexes 
that reflect spinal excitability. Results showed no 
significant changes in F wave minimal latency, H-reflex 
latency, or H-M ratio after treatment. Therefore, those 
factors can be eliminated as the mechanism by which 
ESWT reduces spasticity by decreasing spinal excitability. 
Manganotti and Amelio
20 also reported that the eff  ect of 
ESWT on spinal excitability can be excluded as the main 
mechanism, because no change of F wave latency or 
amplitude after treatment was demonstrated.
  Another possible mechanism was mechanical vibratory 
stimulation, which reduces excitability of motor neurons 
and induces the change of F wave.
29 In this study, we 
can rule out this theory because no significant change 
of F wave or H-reflex were detected. Considering the 
clinical anti-spastic effect observed up to 4 weeks after 
treatment,
20 mechanical vibratory stimulation, which is 
transitory and short lasting, could also be excluded as a 
major eff  ect.
  Because the latency and amplitude of compound 
muscle action potential and conduction velocity of tibial 
nerve were not changed in this study, we can rule out a 
significant effect of ESWT on peripheral nerves and the 
eff  ect of botulinum toxin A on neuromuscular blockage. 
  Results of this study could not reveal the exact mecha-
nism of ESWT for reducing spasticity. However, we 
can rule out several proposed mechanisms such as 
decreased spinal excitability, peripheral nerve injury, 
and mechanical vibratory stimulation by using electro-
physiologic studies. It was previously reported that 
range of motion of the joint increased after ESWT;
20,21 
however, we did not evaluate range of motion of the joint 
in the study, and therefore the mechanisms proposed 
by Maganotti and Amelio
20 for reducing spasticity 
mediated by improving stiffness of connective tissue Spasticity and Electrophysiologic  Changes after ESWT
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aff  ecting fi  brosis of chronic hypertonic muscles were not 
confi  rmed in this study .
Similar to previous studies performed in stroke patients 
with upper limb spasticity, an immediate therapeutic 
effect of ESWT in reducing spasticity was found for 
stroke patients with ankle spasticity. ESWT can reduce 
spasticity in stroke patients with lower limb spasticity 
and prevent complications of spasticity, such as equi-
novarus deformity. This study only measured the 
immediate eff  ect of ESWT, but Manganotti and Amelio
20 
and Yoo et al.
21 reported that the therapeutic effect of 
ESWT on upper limb spasticity could last at least 4 weeks, 
maximally 12 weeks, and that ESWT had a therapeutic 
effect on reducing spasticity for a considerable time. 
There were several cases where the patient complained 
of pain during treatment, but the degree of pain was not 
severe (< VAS 3), and not all subjects reported pain after 
treatment; other side eff  ects were not found in this study. 
ESWT appears to be safe and noninvasive and can reduce 
fi  nancial burden compared to treatment using botulinum 
toxin A. ESWT can be helpful in treatment of chronic 
stroke patients with spasticity.
  There are several limitations in this study. First, the 
mechanism of ESWT for reducing spasticity was not fully 
evaluated in this study. Further studies are needed to 
elucidate the mechanism of ESWT for reducing spasticity 
by comparing the anti-spastic effects; for example, 
stiffness of connective tissue for acute stroke patients 
compared with chronic stroke patients. Second, this 
study used F wave minimal latency to assess the spinal 
excitability instead of F wave amplitude or F-M ratio, 
which are well known and widely used. Further studies 
concerning the correlation between F wave minimal 
latency and spinal excitability are needed. Th  ird,  similar 
to results from previous studies conducted for upper 
limb spasticity,
20,21 range of motion of the joint should 
be measured. Reduced eff  ect of spasticity on functional 
abilities such as ambulation or activities of daily living 
should be assessed. Finally, further studies concerning 
the most effective level of intensity, number of ESWT 
treatments,  and duration of therapeutic effect, need to 
be conducted in a larger number of patients.
CONCLUSION
  In this study, 1 session of ESWT for chronic stroke 
patients with ankle plantarfl  exor spasticity produced an 
immediate effect. There were no significant changes in 
electrophysiologic studies such as F wave, H-reflex, or 
tibial nerve conduction studies after treatment. ESWT 
appears to be safe and noninvasive, and can reduce 
fi  nancial burden compared to treatment with botulinum 
toxin A. ESWT can be helpful for treatment of stroke 
patients with spasticity, prevention of complications such 
as equinovarus deformity, and result in a more stable gait 
pattern. Further studies in larger numbers of patients on 
functional changes produced by reduced spasticity, the 
most eff  ective treatment protocol for ESWT, and duration 
of therapeutic eff  ect, are warranted.
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